GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/NON-RI) - Evolution Group Plc

21 Dec 2011 11:51

RNS Number : 4172U
Credit Suisse Securities (Eur) Ltd
21 December 2011
 



FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Credit Suisse Securities (Europe) Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Evolution Group Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Evolution Group Plc

(d) Date position held/dealing undertaken:

20-December-2011

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

NO

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

193

0.0001

15,796

-0.0324

(2) Derivatives (other than options):

(3) Options and agreements to purchase/sell:

TOTAL:

193

0.0001

15,796

-0.0324

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

Number of securities

Price per unit

Ordinary shares

B

390727

76.00

Ordinary shares

S

324935

76.00

Ordinary shares

B

386095

75.98

Ordinary shares

S

386095

75.98

Ordinary shares

S

21051

75.97

Ordinary shares

B

457686

75.96

Ordinary shares

S

457686

75.96

Ordinary shares

S

7000

75.95

Ordinary shares

B

19532

75.92

Ordinary shares

S

19532

75.92

Ordinary shares

S

47700

75.90

Ordinary shares

B

26231

75.89

Ordinary shares

S

26231

75.89

Ordinary shares

S

13000

75.86

Ordinary shares

S

20000

75.82

Ordinary shares

S

7000

75.77

Ordinary shares

B

65554

75.75

Ordinary shares

S

17000

75.73

Ordinary shares

B

1405

75.50

 

Purchases 1,347,230

Sales 1,347,230

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

21-December-2011

Contact name:

Liane Agostini / Anthony Allen / Paul MacDonald

Telephone number:

0207 888 3599 / 5416 / 8548

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEODKDDPDBDDKBB
Date   Source Headline
17th Jun 20207:00 amRNSSFX-01 to be evaluated in COVID-19 trial
15th Jun 20205:05 pmRNSHolding(s) in Company
15th Jun 20207:00 amRNSFinal Results
8th Jun 20207:00 amRNSPaper on SFX-01 in ER positive breast cancer
5th Jun 20207:00 amRNSNotice of Results
15th May 202012:30 pmRNSStatement Re: Share Price Movement
30th Apr 20207:00 amRNSDirectorate Change
20th Feb 20209:27 amRNSHolding(s) in Company
13th Feb 20207:00 amRNSUniversity of Rochester Collaboration
6th Feb 20207:00 amRNSUniversity of Manchester collaboration discovery
29th Jan 20202:05 pmRNSSecond Price Monitoring Extn
29th Jan 20202:00 pmRNSPrice Monitoring Extension
20th Jan 20203:39 pmRNSHolding(s) in Company
17th Jan 20203:32 pmRNSHolding(s) in Company
8th Jan 20209:52 amRNSHolding(s) in Company
17th Dec 20197:01 amRNSInvestor presentation
17th Dec 20197:00 amRNSHalf-year Report
5th Dec 20197:00 amRNSMOU with The University of Dundee
4th Dec 20193:11 pmRNSNotice of Results
14th Nov 201911:59 amRNSHolding(s) in Company
11th Nov 201912:11 pmRNSSAS study clarification
11th Nov 20197:00 amRNSSFX-01 results in SAS study
30th Sep 20197:00 amRNSESMO presentation of Phase II STEM clinical data
23rd Sep 20197:00 amRNSUpdate on extended-use phase of STEM trial
5th Sep 20197:00 amRNSAgreement for supply of SFX-01 for autism trial
28th Aug 20197:00 amRNSUpdate on SAS study
7th Aug 20197:00 amRNSGrant of further European patent
5th Aug 20197:00 amRNSResearch collaboration
25th Jul 20191:00 pmRNSGrant of Options
18th Jul 20193:47 pmRNSResult of AGM
18th Jul 20197:00 amRNSAGM Statement
24th Jun 20197:00 amRNSSFX-01 featured in SAH review paper
19th Jun 201910:39 amRNSPosting of Annual Report and AGM Notice
13th Jun 20197:00 amRNSFull Year Results
11th Jun 20197:00 amRNSNotification of Preliminary Results
22nd May 20191:32 pmRNSHolding(s) in Company
21st May 20197:00 amRNSShare Option Exercise and Issue of Equity
9th May 20195:49 pmRNSHolding(s) in Company
9th May 201910:11 amRNSHolding(s) in Company
8th May 201911:29 amRNSResult of GM and Completion of Placing
26th Apr 201911:05 amRNSSecond Price Monitoring Extn
26th Apr 201911:00 amRNSPrice Monitoring Extension
24th Apr 201911:37 amRNSHolding(s) in Company
24th Apr 201911:33 amRNSHolding(s) in Company
23rd Apr 20192:05 pmRNSSecond Price Monitoring Extn
23rd Apr 20192:00 pmRNSPrice Monitoring Extension
23rd Apr 201910:30 amRNSHolding(s) in Company
18th Apr 20195:30 pmRNSPosting of Circular and Timing of General Meeting
17th Apr 20191:00 pmRNSPlacing and Notice of General Meeting
2nd Apr 20199:00 amRNSfinnCap publishes initiation research

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.